Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

Philogen announced Option and License Agreement with Pfizer Inc.

Dec 22, 2014 | 2014, Press Releases, Scientific

Philogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates and targeted nano particles. (see full press release). Siena (Italy), December 22nd, 2014.

Dario Neri – presented ‘Immunocytokines for the therapy of cancer and of chronic inflammation’ at Antibody Engineering and Therapeutics conference

Dec 7, 2014 | 2014, Press Releases, Scientific

Dario Neri – presented ‘Immunocytokines for the therapy of cancer and of chronic inflammation’ at Antibody Engineering and Therapeutics conference. Huntingdon Beach, California (USA), December 7th-11th, 2014.

Recent Posts

  • Philogen to attend the European Bispecific and Multispecific Antibody congress in Amsterdam on the 22nd and 23rd of February, 2023
  • Philogen to attend the 7th Annual Next-Gen Immuno-Oncology Conference congress in London on the 9th and 10th of March, 2023
  • 23 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 16 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 09 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it